annual meeting program - American Society of Clinical Oncology

FRIDAY
Friday, June 4, 2010
Brd. 7 Response of newly diagnosed myeloma with 1q21 amplification to
bortezomib-based PAD induction therapy. (Abstract #8028^)
D. E. Joshua, J. Bashford, J. Szer, N. Horvath, A. Spencer, M. S. Hertzberg,
E. Ashurst, J. Wade, M. C. Copeman, H. M. Prince
Brd. 8 Dose-escalation study of carfilzomib (CFZ) � lenalidomide (LEN) � low-dose
dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R
MM). (Abstract #8029)
W. Bensinger, M. Wang, R. Z. Orlowski, M. Alsina, T. Martin, S. Singhal,
N. Y. Gabrail, M. Vallone, M. Kauffman, R. Niesvizky
Brd. 9 Phase Ib study of oral panobinostat (LBH589) � lenalidomide (LEN) �
dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and
refractory (Ref) multiple myeloma (MM). (Abstract #8030^)
M. Mateos, A. Spencer, K. Taylor, S. Lonial, J. De La Rubia, T. Facon,
B. Bengoudifa, K. Hazell, P. M. Bourquelot, J. F. San-Miguel
Brd. 10 Phase I study of combined vorinostat (V), lenalidomide (L), and
dexamethasone (D) in patients (pts) with relapsed or refractory multiple
myeloma (MM). (Abstract #8031)
P. G. Richardson, D. M. Weber, C. S. Mitsiades, M. A. Dimopoulos, J. Harousseau,
J. Howe, T. Graef, C. Byrne, K. C. Anderson, D. S. Siegel
Brd. 11 Results of a phase I study of RAD001 in combination with lenalidomide in
patients with relapsed or refractory multiple myeloma. (Abstract #8032)
A. K. Mahindra, P. G. Richardson, P. Hari, J. Laubach, I. M. Ghobrial, R. L.
Schlossman, E. Weller, N. C. Munshi, K. C. Anderson, N. S. Raje
Brd. 12 Incorporation of rituximab and liposomal doxorubicin into CODOX-m/IVAC
for HIV-negative and HIV-positive adult patients (pts) with untreated Burkitt’s
lymphoma (BL): Preliminary results of a multicenter phase II study. (Abstract
#8033)
S. A. Gregory, P. M. Barr, C. Nabhan, A. Nukala, L. Gallot, A. Larsen, M. Z. Moll,
S. E. Smith, L. I. Gordon, A. M. Evens
Brd. 13 A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide,
vincristine, and prednisone (DR-COP) in patients with newly diagnosed
AIDS-associated B-cell non-Hodgkin’s lymphoma (ARL): An AIDS
Malignancy Consortium Trial (AMC 047). (Abstract #8034)
A. M. Levine
Brd. 14 HIV-associated Hodgkin’s lymphoma (HIV-HL): Results of a prospective
multicenter trial. (Abstract #8035)
M. Hentrich, M. Berger, C. Hoffmann, J. M. Siehl, T. Wolf, J. Rockstroh,
G. Fätkenheuer, K. Arastéh, F. A. Mosthaf Sr., C. Wyen, German HIV-related
Lymphoma Study Group
Brd. 15 Complete response rates with lenalidomide plus rituximab for untreated
indolent B-cell non-Hodgkin’s lymphoma. (Abstract #8036)
N. H. Fowler, P. McLaughlin, F. B. Hagemeister, L. W. Kwak, M. A. Fanale,
S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, F. Samaniego
Brd. 16 Lenalidomide (LEN) in patients with transformed lymphoma: Results from a
large international phase II study (NHL-003). (Abstract #8037)
C. B. Reeder, J. Vose, T. E. Witzig, P. L. Zinzani, R. Buckstein, J. Polikoff, J. Li,
D. Pietronigro, A. L. Ervin-Haynes, M. S. Czuczman
Brd. 17 Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with
non-germinal center B-cell phenotype to lenalidomide (L) alone or in
combination with rituximab (R). (Abstract #8038)
F. J. Hernandez-Ilizaliturri, G. Deeb, P. L. Zinzani, S. A. Pileri, F. Malik,
W. R. Macon, T. E. Witzig, A. Goy, M. S. Czuczman
Brd. 18 Galiximab, an anti-CD80 primatized monoclonal antibody, in relapsed
Hodgkin lymphoma: Final results of CALGB 50602. (Abstract #8039)
S. M. Smith, N. Bartlett, J. L. Johnson, J. Lister, A. F. Cashen, S. Jung, H. Schöder,
K. Egan, B. D. Cheson
70